Immune checkpoint blockade has revolutionized the treatment for patients with cancer. Great efforts remain to better understand resistant mechanisms to treatment as well as means to improve outcomes via combinatorial approaches. Work included will highlight the success of immune checkpoint blockade in melanoma as an example as well as propose further combinations by targeting innate immunity and angiogenesis for potential synergistic effects. Proposed novel targets will be discussed with correlative data.
1. To identify patients and biomarkers predictive of responses to checkpoint blockade
2. To better understand combinatorial approached with immune checkpoint blockade by further targeting the tumor microenvironment